Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share
February 02, 2024 07:00 ET
|
Sio Gene Therapies, Inc.
PARSIPPANY, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. ("Sio") today announced that it expects to file a certificate of dissolution (the "Certificate of Dissolution") with the...
Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results
February 14, 2023 07:00 ET
|
Sio Gene Therapies, Inc.
– Three-Month and Nine-Month Losses decline by 84.2% and 73.5%, respectively – Operating Cash Outflows for the Nine Months Ended December 31, 2022 decreased by $23.8 million or 56% versus the prior...
Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution
December 14, 2022 16:49 ET
|
Sio Gene Therapies, Inc.
NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (Nasdaq:SIOX) today announced that its Board of Directors has determined, after extensive and careful consideration of potential...
Sio Gene Therapies Announces Fiscal Second Quarter 2022 Financial Results
November 10, 2022 07:00 ET
|
Sio Gene Therapies, Inc.
- Three-Month and Six-Month Losses decline by 85.5% and 65.3%, respectively - Operating Cash Outflows for the Six Months Ended September 30, 2022 decreased by $8.1 million or 37% versus the prior...
Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results
August 11, 2022 07:00 ET
|
Sio Gene Therapies, Inc.
— Strong cash position with $54.8 million of cash and cash equivalents as of June 30, 2022, expected to provide cash runway beyond August 2023 NEW YORK, N.Y. and DURHAM, N.C., Aug. 11, 2022 ...
Sio Gene Therapies Provides Update on Cash Position and Major Upcoming GM1 Gangliosidosis Program Milestones
March 15, 2021 07:00 ET
|
Sio Gene Therapies, Inc.
Company had $120.9 million of cash and cash equivalents as of March 12, 2021Substantial increase in liquidity driven by equity investment from Suvretta Capital and sale of Arvelle shares Company...
Sio Gene Therapies to Participate in Upcoming Investor & Scientific Conferences
March 11, 2021 08:00 ET
|
Sio Gene Therapies, Inc.
NEW YORK and RESEARCH TRIANGLE PARK, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically...
Sio Gene Therapies to Present at the 10th Annual SVB Leerink Global Healthcare Conference
February 16, 2021 07:00 ET
|
Sio Gene Therapies, Inc.
NEW YORK and RESEARCH TRIANGLE PARK, N.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically...
Sio Gene Therapies Announces Financial Results for Third Fiscal Quarter Ended December 31, 2020
February 09, 2021 07:00 ET
|
Sio Gene Therapies, Inc.
- Company had $81 million of cash and cash equivalents as of December 31, 2020, and expects to receive additional $16 million in cash in 2021 from sale of Arvelle Therapeutics shares - Cash runway...
Sio Gene Therapies Announces Receipt of $11.6 Million from Closing of the Sale of Arvelle Therapeutics
February 04, 2021 07:00 ET
|
Sio Gene Therapies, Inc.
NEW YORK and RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically...